ABSTRACT
The growth of axons is an intricately regulated process involving intracellular signaling cascades and gene transcription. We had previously shown that the stimulus-dependent transcription factor, serum response factor (SRF), plays a critical role in regulating axon growth in the mammalian brain. However, the molecular mechanisms underlying SRF-dependent axon growth remains unknown. Here we report that SRF is phosphorylated and activated by GSK-3 to promote axon outgrowth in mouse hippocampal neurons. GSK-3 binds to and directly phosphorylates SRF on a highly conserved serine residue. This serine phosphorylation is necessary for SRF activity and for its interaction with MKL-family cofactors, MKL1 and MKL2, but not with TCF-family cofactor, ELK-1. Axonal growth deficits caused by GSK-3 inhibition could be rescued by expression of a constitutively active SRF. The SRF target gene and actin-binding protein, vinculin, is sufficient to overcome the axonal growth deficits of SRF-deficient and GSK-3-inhibited neurons. Furthermore, short hairpin RNA-mediated knockdown of vinculin also attenuated axonal growth. Thus, our findings reveal a novel phosphorylation and activation of SRF by GSK-3 that is critical for SRF-dependent axon growth in mammalian central neurons.
Subject(s)
Axons/enzymology , Glycogen Synthase Kinase 3/metabolism , Serum Response Factor/metabolism , Animals , Female , Glycogen Synthase Kinase 3 beta , HEK293 Cells , Hippocampus/cytology , Humans , Male , Mice , Mice, Transgenic , Nestin/genetics , Neurons/enzymology , Neurons/ultrastructure , Phosphorylation/physiology , Pseudopodia/enzymology , Serine/metabolism , Serum Response Factor/genetics , Trans-Activators/metabolism , Transcription Factors/metabolism , Vinculin/genetics , Vinculin/metabolismABSTRACT
p63 is a member of the p53 tumour suppressor family that includes p73. The p63 gene encodes a protein comprising an N-terminal transactivation domain, a DNA binding domain and an oligomerization domain, but varies in the organization of the C-terminus as a result of complex alternative splicing. p63α contains a C-terminal sterile α motif (SAM) domain that is thought to function as a protein-protein interaction domain. Several missense and heterozygous frame shift mutations, encoded within exon 13 and 14 of the p63 gene, have been identified in the p63α SAM domain in patients suffering from ankyloblepharon-ectodermal dysplasia-clefting syndrome. Here we report the solution and high resolution crystal structures of the p63α SAM domain and investigate the effect of several mutations (L553F/V, C562G/W, G569V, Q575L and I576T) on the stability of the domain. The possible effects of other mutations are also discussed.
Subject(s)
Cleft Lip/genetics , Cleft Palate/genetics , Ectodermal Dysplasia/genetics , Eye Abnormalities/genetics , Protein Interaction Domains and Motifs/genetics , Transcription Factors/chemistry , Transcription Factors/genetics , Tumor Suppressor Proteins/chemistry , Tumor Suppressor Proteins/genetics , Amino Acid Sequence , Crystallization , Crystallography, X-Ray , DNA-Binding Proteins/chemistry , Eyelids/abnormalities , Humans , Models, Molecular , Molecular Sequence Data , Nuclear Magnetic Resonance, Biomolecular , Nuclear Proteins/chemistry , Sequence Alignment , Thermodynamics , Tumor Protein p73ABSTRACT
Growth factors, insulin signaling, and nutrients are important regulators of beta-cell mass and function. The events linking these signals to the regulation of beta-cell mass are not completely understood. The mTOR pathway integrates signals from growth factors and nutrients. Here, we evaluated the role of the mTOR/raptor (mTORC1) signaling in proliferative conditions induced by controlled activation of Akt signaling. These experiments show that the mTORC1 is a major regulator of beta-cell cycle progression by modulation of cyclin D2, D3, and Cdk4 activity. The regulation of cell cycle progression by mTORC1 signaling resulted from modulation of the synthesis and stability of cyclin D2, a critical regulator of beta-cell cycle, proliferation, and mass. These studies provide novel insights into the regulation of cell cycle by the mTORC1, provide a mechanism for the antiproliferative effects of rapamycin, and imply that the use of rapamycin could negatively impact the success of islet transplantation and the adaptation of beta-cells to insulin resistance.
Subject(s)
Cyclins/biosynthesis , Insulin-Secreting Cells/metabolism , Protein Biosynthesis/physiology , Signal Transduction/physiology , Transcription Factors/metabolism , Animals , Cell Cycle , Cell Line , Cell Size , Cyclin D2 , Cyclin D3 , Cyclin-Dependent Kinase 4/genetics , Cyclin-Dependent Kinase 4/metabolism , Cyclins/genetics , Cyclins/metabolism , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/pharmacology , Insulin Resistance/genetics , Insulin-Secreting Cells/cytology , Islets of Langerhans Transplantation , Mechanistic Target of Rapamycin Complex 1 , Mice , Mice, Transgenic , Multiprotein Complexes , Protein Biosynthesis/drug effects , Protein Stability/drug effects , Proteins , Signal Transduction/drug effects , Sirolimus/adverse effects , Sirolimus/pharmacology , TOR Serine-Threonine Kinases , Transcription Factors/geneticsABSTRACT
SCML2 (sex comb on midleg-like 2) is a constituent of the Polycomb repressive complex 1, a large multiprotein assembly required for the repression of developmental control genes. It contains two MBT (malignant brain tumor) repeats; the MBT is a protein module structurally similar to domains that bind to methylated histones. We have used NMR spectroscopy to examine the binding specificity of these repeats. Our data show that they preferentially bind histone peptides monomethylated at lysine residues with no apparent sequence specificity. The crystal structure of the complex between the protein and monomethyllysine reveals that the modified amino acid binds to an aromatic rich pocket at one end of the beta-barrel of the second repeat.
Subject(s)
DNA-Binding Proteins/chemistry , DNA-Binding Proteins/metabolism , Histones/chemistry , Histones/metabolism , Transcription Factors/chemistry , Transcription Factors/metabolism , Binding Sites , DNA-Binding Proteins/genetics , Epigenesis, Genetic , Humans , In Vitro Techniques , Kinetics , Ligands , Lysine/analogs & derivatives , Lysine/chemistry , Methylation , Models, Molecular , Nuclear Magnetic Resonance, Biomolecular , Peptides/chemistry , Peptides/metabolism , Polycomb-Group Proteins , Protein Binding , Protein Conformation , Repetitive Sequences, Amino Acid , Transcription Factors/geneticsABSTRACT
HER4/ErbB4 is a ubiquitously expressed member of the EGF/ErbB family of receptor tyrosine kinases that is essential for normal development of the heart, nervous system, and mammary gland. We report here crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms. Active ErbB4 kinase adopts an asymmetric dimer conformation essentially identical to that observed to be important for activation of the EGF receptor/ErbB1 kinase. Mutagenesis studies of intact ErbB4 in Ba/F3 cells confirm the importance of this asymmetric dimer for activation of intact ErbB4. Lapatinib binds to an inactive form of the ErbB4 kinase in a mode equivalent to its interaction with the EGF receptor. All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. These results demonstrate that key elements of kinase activation and inhibition are conserved among ErbB family members.
Subject(s)
ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Protein Kinase Inhibitors/pharmacology , Animals , Cells, Cultured , Conserved Sequence , Enzyme Activation/drug effects , ErbB Receptors/chemistry , Humans , Lapatinib , Models, Biological , Models, Molecular , Protein Binding , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/metabolism , Protein Structure, Quaternary , Protein Structure, Secondary , Quinazolines/chemistry , Quinazolines/metabolism , Quinazolines/pharmacology , Receptor, ErbB-2/chemistry , Receptor, ErbB-2/metabolism , Receptor, ErbB-4 , SpodopteraABSTRACT
Sex Comb on Midleg (SCM) belongs to the Polycomb group of proteins, which are involved in transcriptional regulation in Drosophila. It is one of the components of Polycomb repressive complex 1, a multiprotein complex of Polycomb group proteins involved in the maintenance of repression and the blocking of chromatin remodeling. SCM contains two approximately 100-residue malignant brain tumor (MBT) repeats at the N terminus. These repeats are also found in other proteins involved in transcriptional repression. Here, we report the 1.78-A crystal structure of the two MBT repeats of SCM-like 2 (SCML2), a human homologue of SCM. Each repeat consists of an extended arm and a beta-barrel core. There are significant structural similarities to the Tudor, PWWP, and chromo domains, suggesting probable evolutionary relationships and functional similarities between the MBT repeats and these domains.
